Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

被引：0
|
作者：
Gutierrez, Martin
Subbiah, Vivek
Nemunaitis, John J.
Mettu, Niharika B.
Papadopoulos, Kyriakos P.
Barve, Minal A.
Feliz, Luis
Lihou, Christine Francis
Tian, Chenwei
Ji, Tao
Silverman, Ian M.
Chugh, Rashmi
Saleh, Mansoor N.
机构：
[1] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[6] Mary Crowley Canc Res Ctr, Dallas, TX USA
[7] Incyte Biosci Int Sarl, Geneva, DE, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3606
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [42] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [43] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [44] EFFICACY AND SAFETY OF SORAFENIB IN ELDERLY PTS: RESULTS FROM A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE III STUDY IN EUROPEAN PTS WITH ADVANCED RCC (EU ARCCS)
    Porta, C.
    Bracarda, S.
    Beck, J.
    Procopio, G.
    Staehler, M.
    Strauss, U. P.
    Burrock, K.
    Mersmann, S.
    Eisen, T.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 193 - 193
  • [45] High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    Nastoupil, Loretta
    Westin, Jason R.
    Fowler, Nathan H.
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Dsouza, Ly
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang Zhiqiang
    Feng, Lei
    Zhou, Shouhao
    Davis, R. Eric
    Neelapu, Sattva S.
    BLOOD, 2017, 130
  • [46] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 14 - 15
  • [47] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [48] MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours
    Domchek, S.
    Bang, Y-J
    Coukos, G.
    Kobayashi, K.
    Baker, N.
    McMurtry, E.
    Song, W.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Safety, tolerability, and preliminary efficacy of tinodasertib as a monotherapy or in combination with pembrolizumab or irinotecan in metastatic colorectal cancer: Interim results from a phase II open-label, dose-finding, run-in and cohort expansion study.
    Matos, Marco
    Kannourakis, George
    Aghmesheh, Morteza
    Mendis, Shehara Ramyalini
    Mahon, Kate
    Dave, Harish P.
    Barde, Prajak J.
    Schwedat, Anke
    Patava, John
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 183 - 183
  • [50] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Anthony W. Tolcher
    Leonard J. Appleman
    Geoffrey I. Shapiro
    Alain C. Mita
    Frank Cihon
    Arthur Mazzu
    Pavur R. Sundaresan
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 751 - 764
12345